Aleph (psychedelic)


Aleph, also recognized as DOT or 2,5-dimethoxy-4-methylthioamphetamine, belongs to the class of substituted amphetamines within the phenethylamine compound group, renowned for its hallucinogenic properties. This compound can serve as a psychedelic drug and is often employed as an entheogen. The distinguished chemist Alexander Shulgin pioneered its synthesis and bestowed the name “Aleph” in homage to the primary letter of the Hebrew alphabet. In the enlightening pages of his book PiHKAL, Shulgin specifies a recommended dosage range of 5–10 mg, typically yielding effects that endure for a duration of 6 to 8 hours.
Like other psychedelic substances, Aleph functions as a partial agonist at the 5-HT2A receptor, displaying an EC50 value of 10 nM. It possesses a relatively modest MAO-A inhibitory activity, indicated by an IC50 of 5.2 μM. To put this into perspective, the IC50 of amphetamine stands at 11 μM, whereas 4-methylthioamphetamine showcases a value of 0.2 μM. A lower IC50 value denotes a more robust inhibitory effect.

CAS Number61638-07-1 
3D model (JSmol)Interactive imageInteractive image
CompTox Dashboard(EPA)DTXSID80874362


In the United States, Aleph is categorized as a Schedule 1 controlled substance due to its classification as a positional isomer of 2C-T-4 and 2C-T-7.


1. What is Aleph?

  • Aleph, also known as DOT or 2,5-dimethoxy-4-methylthioamphetamine, is a psychedelic substance within the phenethylamine class of compounds. It is recognized for its hallucinogenic effects and is sometimes used as an entheogen.

2. Who first synthesized Aleph?

  • Aleph was first synthesized by the notable chemist Alexander Shulgin, who named it after the first letter of the Hebrew alphabet.

3. How is Aleph typically consumed?

  • Aleph is usually consumed orally, with a recommended dosage range of 5–10 milligrams. Effects typically last for 6 to 8 hours.

4. What are the effects of Aleph?

  • Aleph is known for inducing psychedelic experiences, including alterations in perception, mood, and consciousness. Users may experience vivid visual and auditory hallucinations, altered thinking, and a connection to a higher spiritual or cosmic reality.

5. Is Aleph legal to possess or use?

  • The legal status of Aleph varies by country and region. It is classified as a Schedule 1 controlled substance in the United States.

6. How does Aleph affect the brain?

  • Like many other psychedelics, Aleph acts as a partial agonist at the 5-HT2A receptor, influencing serotonin receptors in the brain. These interactions are believed to be responsible for the psychedelic effects.

7. Is Aleph safe to use?

  • Like other psychedelics, the safety of using Aleph depends on various factors, including dosage, set and setting, and individual sensitivity. It is essential to approach psychedelic substances cautiously and in a controlled environment to minimize potential risks.

8. Can Aleph be used for therapeutic purposes?

  • Some researchers have explored the therapeutic potential of psychedelics, including Aleph, in treating mental health conditions. However, more research is needed to determine its safety and efficacy in clinical settings.

9. What are the risks associated with Aleph use?

  • Aleph use can lead to unpredictable psychological effects, including anxiety, paranoia, and hallucinogen-induced disorders. It is essential to be informed about these potential risks and take necessary precautions.

10. Where can I find more information about Aleph?

  • For more detailed information on Aleph and its effects, it is advisable to consult scientific literature, research studies, and reputable sources on psychedelic substances. Always prioritize safety and responsible use if considering trying Aleph or any other psychedelic.


  1. In 1991, Alexander Shulgin and Ann Shulgin authored “PiHKAL: A Chemical Love Story,” a captivating exploration of psychoactive compounds and their effects. This book offers intriguing insights into the world of psychedelics and their potential applications. It is a must-read for anyone interested in this field. (ISBN: 0-9630096-0-5; OCLC: 25627628)
  2. In a recent study conducted in January 2023, Halberstadt and colleagues investigated the structure-activity relationships of 4-thio-substituted 2,5-dimethoxyphenylalkylamines. Their research delved into the head-twitch response, shedding light on the effects and interactions of these compounds. This study contributes valuable information to the scientific community. (DOI: 10.1007/s00213-022-06279-2; PMC: 9816194; PMID: 36477925)
  3. An April 2005 study by Gallardo-Godoy and others explored the biological activities of sulfur-substituted alpha-alkyl phenethylamines. It also discussed the use of these compounds as selective and reversible MAO-A inhibitors. The research included CoMFA analysis and active site modeling, providing critical data for understanding the pharmacological properties of these substances. (DOI: 10.1021/jm0493109; PMID: 15801832)
  4. In January 2023, the Drug Enforcement Administration (DEA), under the U.S. Department of Justice, published a document titled “Lists of: Scheduling Actions Controlled Substances Regulated Chemicals.” This comprehensive resource outlines the legal classifications and regulations of various substances. It serves as a reference for individuals seeking information on the legal status of different compounds.

Leave a Comment

Your email address will not be published. Required fields are marked *